Facebook Pixel China's Innovative Approach to Universal Health Coverage | BioSpectrum Asia - business - इस कहानी को Magzter.com पर पढ़ें

कोशिश गोल्ड - मुक्त

China's Innovative Approach to Universal Health Coverage

BioSpectrum Asia

|

BioSpectrum Asia August 2025

China has successfully implemented various medical insurance reforms and development tasks under five principles including promoting equity and accessibility, the rule of law, technological empowerment, coordinated development and safeguarding the security of the fund during the first four years of the 14th Five-Year Plan (the 2021-2025 period).

- Narayan Kulkarni

The authorities nationwide have spent about 72.3 billion yuan (about $10.1 billion) to assist people from disadvantaged groups, providing support for 350 million instances of insurance coverage. China's basic medical insurance has maintained a coverage rate of around 95 per cent, with over 1.32 billion people enrolled in 2024. Medical assistance schemes cover approximately 80 million people in China each year, helping to ensure that they can benefit from the insurance programme.

From 2021 to 2024, nearly 20 billion medical visits received medical insurance reimbursement, a 1.6-fold increase from 2020. As of June 2025, 253 million people had participated in maternity insurance, with cumulative fund expenditures of 438.3 billion yuan and 96.1432 million benefits received. China has also optimised the "one-stop birth" process, allowing newborns to enroll in insurance with just a birth certificate. Thirty-one provinces and the Xinjiang Production and Construction Corps have included assisted reproductive services in medical insurance reimbursement. Nearly 60 per cent of coordinated regions nationwide provide direct maternity benefits to insured female employees.

BioSpectrum Asia

यह कहानी BioSpectrum Asia के BioSpectrum Asia August 2025 संस्करण से ली गई है।

हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।

क्या आप पहले से ही ग्राहक हैं?

BioSpectrum Asia से और कहानियाँ

BioSpectrum Asia

How FemTech Spurt in APAC is Redefining Healthcare

Despite representing half the global population, women's health has historically received only a fraction of healthcare innovation and investment.

time to read

4 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

China's Colossal Ageing Population and Low Birth Rate Challenge

China's recent policy initiatives pertaining to long-term care insurance, maternity insurance expansion, and primary healthcare reform reflect a coordinated attempt to address deep structural demographic challenges—most notably 'rapid population ageing' and declining birth rates.

time to read

2 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

"We need to prioritise research as several common AYA cancers are significantly under-studied in Asian populations"

At the SingHealth Presidents' Scientific and Partners in Social-care (SPSOC) Conference, Assistant Professor Eileen Poon, Senior Consultant in Medical Oncology at the National Cancer Centre Singapore (NCCS) delivered an enlightening presentation.

time to read

7 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

Shimadzu Scientific Instruments opens laboratory in San Francisco Bay Area

Shimadzu Scientific Instruments (SSI) has opened its new research and development (R&D) facility in South San Francisco, California, US.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

NTU and NHG Health partner to advance healthcare education in Singapore

NHG Health's inaugural E3 (Educate, Elevate, Evolve) conference, held recently, was marked by a new partnership with Nanyang Technological University (NTU) Singapore, signalling a significant step in advancing healthcare education through interdisciplinary collaboration.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

"Building a lean team with deep operational expertise increases likelihood of success in rare disease drug development"

More than 300 million people worldwide are impacted by over 10,000 rare diseases, i.e. more than cancer and AIDS combined.

time to read

5 mins

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Qiagen expands into bloodstream infection syndromic testing with new rapid QIAstat-Dx panel

Qiagen N.V. has announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR Panel.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Royalty Pharma on-boards Kenneth Sun as Senior Vice President and Head of Asia

US-based Royalty Pharma ple has announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

BioSpectrum Asia

Waters launches omniDAWN Multi-Angle Light Scattering (MALS) Photometer

US-based Waters Corporation has announced the launch of the Waters omniDAWN Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

time to read

1 min

BioSpectrum Asia May 2026

BioSpectrum Asia

South Korea's Cell and Gene Therapy Surge

South Korea's cell and gene therapy (CGT) landscape is highly dynamic, as observed from regulatory approvals, clinical development, and manufacturing activity.

time to read

5 mins

BioSpectrum Asia May 2026

Listen

Translate

Share

-
+

Change font size